EUCTR2004-002171-16-IT进行中（未招募）不适用
Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The EINSTEIN-DVT dose-finding study
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BAYER
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Once-daily oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis. The Einstein-DVT dose-finding study.Acute symptomatic deep-vein thrombosisCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12605000597695Bayer Australia Ltd520
进行中（未招募）
1 期
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyEUCTR2004-002171-16-DKBayer HealthCare AG
进行中（未招募）
不适用
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyEUCTR2004-002171-16-SEBayer HealthCare AG520
进行中（未招募）
不适用
Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study. - Einstein-DVT dose-finding studyAcute symptomatic deep vein thrombosisMedDRA version: 7.0Classification code 10051055EUCTR2004-002171-16-CZBayer HealthCare AG520
进行中（未招募）
1 期
Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein ThrombosisODIXa-DVTA prospective, randomized, multinational, multicenter, partially blinded, parallel-group, open-label active comparator controlled phase II Dose Finding and Proof of Principle Trial. - ODIXa-DVTEUCTR2004-001083-43-GBBayer HealthCare AG